Aferrix
Diagnostic Tools for Iron Toxicity in Body Fluids
Company Overview
Snapshot
Founded in February 2002 by Ioav Cabantchik, Aferrix operates with 1–10 employees. The company holds one patent and focuses on diagnostic tools for iron toxicity. Aferrix ceased operations in January 2023.
Business overview
Aferrix develops advanced diagnostic tools for the early detection and monitoring of serum iron toxicity. The company's core technology includes methods to quantify various forms of toxic iron that are not identified by conventional tests. Aferrix provides iron testing services and kits to research and treatment centers specializing in iron overload diseases, such as thalassemia, hemochromatosis, and myelodysplastic syndrome, as well as to pharmaceutical companies developing iron chelators. All of its products are CE marked for IVD use, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices and Diagnostics Devices.
Log in to access full profile ›Company Intelligence Q&A
- What is Aferrix's primary focus?
- Aferrix specializes in developing diagnostic tools for the early detection and monitoring of serum iron toxicity, offering methods to quantify toxic iron forms not identified by conventional tests.
- When was Aferrix founded?
- Aferrix was founded in February 2002.
- Who is a founder of Aferrix?
- Ioav Cabantchik is a founder of Aferrix.
- What is the operational status of Aferrix?
- Aferrix ceased to operate in January 2023.
- What markets does Aferrix serve?
- Aferrix offers its iron testing services and kits to research and treatment centers specializing in iron overload diseases and to pharmaceutical companies developing iron chelators, with a presence in geomarkets such as India.